조현병 치료제 시장 규모, 점유율, 성장 및 세계 산업 분석 : 유형별, 용도별, 지역별 인사이트와 예측(2026-2034년)

Growth Factors of schizophrenia drugs Market

The global schizophrenia drugs market represents a critical segment of the central nervous system (CNS) therapeutics landscape, addressing a severe and chronic psychiatric disorder that significantly impacts cognitive, emotional, and behavioral functioning. Schizophrenia is classified as a psychotic disorder and is characterized by symptoms such as delusions, hallucinations, disorganized thinking, and impaired judgment. Although the condition cannot be cured, it can be effectively managed through lifelong pharmacological treatment, primarily using antipsychotic medications.

Market Size and Forecast

According to Fortune Business Insights, the global schizophrenia drugs market was valued at USD 9.08 billion in 2025. The market is projected to reach USD 9.48 billion in 2026 and further expand to USD 13.41 billion by 2034, registering a CAGR of 4.43% during the forecast period (2026-2034).

The steady growth of the market is supported by rising disease awareness, increasing diagnosis rates, growing adoption of advanced antipsychotic therapies, and continuous innovation in drug development.

Market Overview

Schizophrenia requires long-term treatment with antipsychotic drugs, even after symptom remission, to prevent relapse. These medications primarily act by regulating dopamine activity in the brain. Over recent decades, schizophrenia treatment has undergone a major transition from first-generation (typical) antipsychotics to second- and third-generation (atypical) antipsychotics, driven by improved efficacy and reduced side-effect profiles.

First-generation antipsychotics were associated with severe extrapyramidal side effects such as rigidity, tremors, akathisia, dystonia, and tardive dyskinesia. These limitations accelerated the adoption of newer drug classes with better safety outcomes.

Key Market Drivers

One of the primary drivers of the schizophrenia drugs market is increased awareness of mental health disorders, supported by government initiatives and healthcare reforms. In countries such as the United States, federal and state mandates require parity in reimbursement for mental and physical healthcare, improving patient access to advanced schizophrenia treatments.

Another major driver is the strong R&D pipeline, with several drugs under development despite regulatory and clinical trial challenges. The industry focus is increasingly shifting toward treatments with fewer relapses, better patient adherence, and minimal adverse effects.

Shift Toward Long-Acting Injectables (LAIs)

Non-adherence to oral antipsychotic medication is a major challenge in schizophrenia treatment and often leads to symptom relapse and irreversible cognitive damage. This has accelerated the adoption of long-acting injectable (LAI) antipsychotics, which improve adherence and reduce relapse rates.

In 2026, injectable-based treatments are projected to account for a 73.46% market share, highlighting their growing clinical importance. FDA approvals such as Perseris (extended-release risperidone) further reinforce this trend.

Market Segmentation Analysis

By Therapeutic Class

The market is segmented into second-generation, third-generation, and other antipsychotics.

The second-generation antipsychotics segment is expected to generate the highest revenue during the forecast period due to superior efficacy and fewer side effects.

Third-generation drugs, including ABILIFY and ABILIFY MAINTENA, also contribute significantly, while first-generation drugs remain relevant for treatment-resistant patients.

By Treatment Type

Schizophrenia treatment is categorized into oral and injectable therapies.

The injectable segment is witnessing faster growth due to better adherence and reduced relapse risk. However, oral formulations are projected to account for 85.21% market share in 2026, reflecting their continued widespread use.

By Distribution Channel

Hospital pharmacies dominated the market, accounting for 38.55% share in 2026, supported by psychiatrist-led treatment and administration of LAIs. Retail and online pharmacies follow, with online pharmacies expected to register the highest CAGR due to increasing digital access.

Regional Analysis

North America dominated the schizophrenia drugs market with a 62.91% share in 2025, generating USD 5.97 billion in revenue in 2026. The U.S. market alone is projected to reach USD 5.67 billion by 2026, driven by advanced therapeutics and favorable reimbursement policies.

The Asia Pacific region is expected to witness the highest growth, with Japan reaching USD 0.58 billion, China USD 0.39 billion, and India USD 0.19 billion by 2026. Europe is also experiencing steady growth, led by Germany, the U.K., and France.

Competitive Landscape

Key players include H. Lundbeck A/S, Otsuka Pharmaceutical Co., Ltd., Janssen Pharmaceuticals, Eli Lilly, AstraZeneca, Alkermes plc, and Bristol-Myers Squibb Company. Market participants are actively investing in LAIs, next-generation antipsychotics, and novel mechanisms such as muscarinic receptor agonists.

Conclusion

In conclusion, the global schizophrenia drugs market is expected to grow steadily from USD 9.08 billion in 2025 to USD 13.41 billion by 2034, driven by increasing mental health awareness, strong R&D pipelines, and rising adoption of second- and third-generation antipsychotics. The growing preference for long-acting injectable therapies and supportive healthcare policies will continue to improve treatment outcomes and sustain long-term market growth across both developed and emerging regions.

Segmentation By Therapeutic Class

• Second Generation
• Third Generation
• Others

By Treatment

• Oral
• Injectable

By Distribution Channel

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
• Others

By Geography

• North America (U.S. and Canada)
• Europe (U.K., Germany, France, Italy, Spain, Scandinavia, and Rest of Europe)
• Asia Pacific (Japan, China, India, Australia, Southeast Asia, and Rest of Asia Pacific)
• Latin America (Brazil, Mexico, and Rest of Latin America)
• Middle East & Africa (South Africa, GCC and Rest of Middle East & Africa)

Table of Content

1. Introduction

• 1.1. Research Scope
• 1.2. Market Segmentation
• 1.3. Research Methodology
• 1.4. Definitions and Assumptions

2. Executive Summary

3. Market Dynamics

• 3.1. Market Drivers
• 3.2. Market Restraints
• 3.3. Market Opportunities

4. Key Insights

• 4.1. Increasing Adoption of Long Acting Injectable (LAIs) as a Form of Treatment
• 4.2. Prevalence of Schizophrenia Disorders by Key Regions
• 4.3. New Product Launches
• 4.4. Pipeline Analysis
• 4.5. Regulatory Scenario By Key Regions
• 4.6. Analysis of First Generation Antipsychotics versus Second & Third Generation Antipsychotics
• 4.7. Overview of R&D Initiatives in Schizophrenia Treatment

5. Global Schizophrenia Drugs Market Analysis, Insights and Forecast, 2021-2034

• 5.1. Key Findings / Summary
• 5.2. Market Analysis, Insights and Forecast - By Therapeutic Class
  • 5.2.1. Third Generation Antipsychotics
  • 5.2.2. Second Generation Antipsychotics
  • 5.2.3. Others
• 5.3. Market Analysis, Insights and Forecast - By Treatment
  • 5.3.1. Oral
  • 5.3.2. Injectable
• 5.4. Market Analysis, Insights and Forecast - By Distribution Channel
  • 5.4.1. Hospital Pharmacies
  • 5.4.2. Retail Pharmacies
  • 5.4.3. Online Pharmacies
  • 5.4.4. Others
• 5.5. Market Analysis, Insights and Forecast - By Region
  • 5.5.1. North America
  • 5.5.2. Europe
  • 5.5.3. Asia Pacific
  • 5.5.4. Latin America
  • 5.5.5. Middle East & Africa

6. North America Schizophrenia Drugs Market Analysis, Insights and Forecast, 2021-2034

• 6.1. Key Findings / Summary
• 6.2. Market Analysis - By Therapeutic Class
  • 6.2.1. Third Generation Antipsychotics
  • 6.2.2. Second Generation Antipsychotics
  • 6.2.3. Others
• 6.3. Market Analysis - By Treatment
  • 6.3.1. Oral
  • 6.3.2. Injectable
• 6.4. Market Analysis - By Distribution Channel
  • 6.4.1. Hospital Pharmacies
  • 6.4.2. Retail Pharmacies
  • 6.4.3. Online Pharmacies
  • 6.4.4. Others
• 6.5. Market Analysis - By Country
  • 6.5.1. U.S.
  • 6.5.2. Canada

7. Europe Schizophrenia Drugs Market Analysis, Insights and Forecast, 2021-2034

• 7.1. Key Findings / Summary
• 7.2. Market Analysis - By Therapeutic Class
  • 7.2.1. Third Generation Antipsychotics
  • 7.2.2. Second Generation Antipsychotics
  • 7.2.3. Others
• 7.3. Market Analysis - By Treatment
  • 7.3.1. Oral
  • 7.3.2. Injectable
• 7.4. Market Analysis - By Distribution Channel
  • 7.4.1. Hospital Pharmacies
  • 7.4.2. Retail Pharmacies
  • 7.4.3. Online Pharmacies
  • 7.4.4. Others
• 7.5. Market Analysis - By Country/ Sub-Region
  • 7.5.1. U.K.
  • 7.5.2. Germany
  • 7.5.3. France
  • 7.5.4. Spain
  • 7.5.5. Italy
  • 7.5.6. Scandinavia
  • 7.5.7. Rest of Europe

8. Asia Pacific Schizophrenia Drugs Market Analysis, Insights and Forecast, 2021-2034

• 8.1. Key Findings / Summary
• 8.2. Market Analysis - By Therapeutic Class
  • 8.2.1. Third Generation Antipsychotics
  • 8.2.2. Second Generation Antipsychotics
  • 8.2.3. Others
• 8.3. Market Analysis - By Treatment
  • 8.3.1. Oral
  • 8.3.2. Injectable
• 8.4. Market Analysis - By Distribution Channel
  • 8.4.1. Hospital Pharmacies
  • 8.4.2. Retail Pharmacies
  • 8.4.3. Online Pharmacies
  • 8.4.4. Others
• 8.5. Market Analysis - By Country/ Sub-Region
  • 8.5.1. Japan
  • 8.5.2. China
  • 8.5.3. India
  • 8.5.4. Australia
  • 8.5.5. Southeast Asia
  • 8.5.6. Rest of Asia Pacific

9. Latin America Schizophrenia Drugs Market Analysis, Insights and Forecast, 2021-2034

• 9.1. Key Findings / Summary
• 9.2. Market Analysis - By Therapeutic Class
  • 9.2.1. Third Generation Antipsychotics
  • 9.2.2. Second Generation Antipsychotics
  • 9.2.3. Others
• 9.3. Market Analysis - By Treatment
  • 9.3.1. Oral
  • 9.3.2. Injectable
• 9.4. Market Analysis - By Distribution Channel
  • 9.4.1. Hospital Pharmacies
  • 9.4.2. Retail Pharmacies
  • 9.4.3. Online Pharmacies
  • 9.4.4. Others
• 9.5. Market Analysis - By Country/ Sub-Region
  • 9.5.1. Brazil
  • 9.5.2. Mexico
  • 9.5.3. Rest of Latin America

10. Middle East & Africa Schizophrenia Drugs Market Analysis, Insights and Forecast, 2021-2034

• 10.1. Key Findings / Summary
• 10.2. Market Analysis - By Therapeutic Class
  • 10.2.1. Third Generation Antipsychotics
  • 10.2.2. Second Generation Antipsychotics
  • 10.2.3. Others
• 10.3. Market Analysis - By Treatment
  • 10.3.1. Oral
  • 10.3.2. Injectable
• 10.4. Market Analysis - By Distribution Channel
  • 10.4.1. Hospital Pharmacies
  • 10.4.2. Retail Pharmacies
  • 10.4.3. Online Pharmacies
  • 10.4.4. Others
• 10.5. Market Analysis - By Country/ Sub-Region
  • 10.5.1. GCC Countries
  • 10.5.2. South Africa
  • 10.5.3. Rest of Middle East & Africa

11. Competitive Analysis

• 11.1. Key Industry Developments
• 11.2. Global Market Share Analysis (2025)
• 11.3. Competition Dashboard
• 11.4. Comparative Analysis - Major Players
• 11.5. Company Profiles
  • 11.5.1. H. Lundbeck A/S
    • 11.5.1.1. Overview
    • 11.5.1.2. Products & services
    • 11.5.1.3. SWOT Analysis
    • 11.5.1.4. Recent Developments
    • 11.5.1.5. Strategies
    • 11.5.1.6. Financials (Based on Availability)
  • 11.5.2. Otsuka Pharmaceutical Co., Ltd.
    • 11.5.2.1. Overview
    • 11.5.2.2. Products & services
    • 11.5.2.3. SWOT Analysis
    • 11.5.2.4. Recent Developments
    • 11.5.2.5. Strategies
    • 11.5.2.6. Financials (Based on Availability)
  • 11.5.3. Janssen Pharmaceuticals, Inc.
    • 11.5.3.1. Overview
    • 11.5.3.2. Products & services
    • 11.5.3.3. SWOT Analysis
    • 11.5.3.4. Recent Developments
    • 11.5.3.5. Strategies
    • 11.5.3.6. Financials (Based on Availability)
  • 11.5.4. Eli Lilly and Company
    • 11.5.4.1. Overview
    • 11.5.4.2. Products & services
    • 11.5.4.3. SWOT Analysis
    • 11.5.4.4. Recent Developments
    • 11.5.4.5. Strategies
    • 11.5.4.6. Financials (Based on Availability)
  • 11.5.5. AstraZeneca
    • 11.5.5.1. Overview
    • 11.5.5.2. Products & services
    • 11.5.5.3. SWOT Analysis
    • 11.5.5.4. Recent Developments
    • 11.5.5.5. Strategies
    • 11.5.5.6. Financials (Based on Availability)
  • 11.5.6. ALLERGAN
    • 11.5.6.1. Overview
    • 11.5.6.2. Products & services
    • 11.5.6.3. SWOT Analysis
    • 11.5.6.4. Recent Developments
    • 11.5.6.5. Strategies
    • 11.5.6.6. Financials (Based on Availability)
  • 11.5.7. Vanda Pharmaceuticals Inc.
    • 11.5.7.1. Overview
    • 11.5.7.2. Products & services
    • 11.5.7.3. SWOT Analysis
    • 11.5.7.4. Recent Developments
    • 11.5.7.5. Strategies
    • 11.5.7.6. Financials (Based on Availability)
  • 11.5.8. Sumitomo Dainippon Pharma Co., Ltd.
    • 11.5.8.1. Overview
    • 11.5.8.2. Products & services
    • 11.5.8.3. SWOT Analysis
    • 11.5.8.4. Recent Developments
    • 11.5.8.5. Strategies
    • 11.5.8.6. Financials (Based on Availability)
  • 11.5.9. Alkermes plc
    • 11.5.9.1. Overview
    • 11.5.9.2. Products & services
    • 11.5.9.3. SWOT Analysis
    • 11.5.9.4. Recent Developments
    • 11.5.9.5. Strategies
    • 11.5.9.6. Financials (Based on Availability)
  • 11.5.10. Bristol-Myers Squibb Company
    • 11.5.10.1. Overview
    • 11.5.10.2. Products & services
    • 11.5.10.3. SWOT Analysis
    • 11.5.10.4. Recent Developments
    • 11.5.10.5. Strategies
    • 11.5.10.6. Financials (Based on Availability)
  • 11.5.11. Other Prominent Players
    • 11.5.11.1. Overview
    • 11.5.11.2. Products & services
    • 11.5.11.3. SWOT Analysis
    • 11.5.11.4. Recent Developments
    • 11.5.11.5. Strategies
    • 11.5.11.6. Financials (Based on Availability)

12. Strategic Recommendations